Vor Bio to present Phase 3 clinical data on telitacicept for generalized myasthenia gravis at upcoming medical conference.
Quiver AI Summary
Vor Bio announced that it will present 48-week clinical data from a Phase 3 study of telitacicept in adults with generalized myasthenia gravis at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting from October 29 to November 1, 2025. This study, sponsored by RemeGen Co., Ltd, showed a significant improvement in the Myasthenia Gravis Activities of Daily Living scale at 24 weeks. Telitacicept is a dual-target fusion protein aimed at treating autoimmune diseases by inhibiting key cytokines that affect B cell survival, and it has already been approved in China for several conditions. Vor Bio is advancing its clinical development with a global trial for generalized myasthenia gravis to gain potential approvals in major markets. The disease affects tens of thousands of patients worldwide, highlighting the need for effective therapies.
Potential Positives
- Presentation of 48-week Phase 3 clinical data at a prestigious medical conference highlights the company's commitment to advancing its novel treatment for autoimmune diseases.
- Telitacicept shows promising results with a significant improvement in patient-reported outcomes, indicating its potential effectiveness in treating generalized myasthenia gravis.
- The drug's existing approvals in China for other serious autoimmune diseases may enhance trust and interest from potential partners and investors.
- The ongoing global Phase 3 trial demonstrates the company's strategic approach to gaining regulatory approval in major international markets, expanding its reach and potential impact on patient care.
Potential Negatives
- The press release highlights that the Phase 3 study results were only presented in China, which may raise concerns about the generalizability of the findings to other regions.
- The mention of existing therapies for generalized myasthenia gravis indicates high competition in the market, which could challenge telitacicept's potential market uptake.
- As telitacicept is still in Phase 3 clinical trials globally, the lack of approval in key markets like the U.S., Europe, and Japan may pose significant risks to future commercial success.
FAQ
What is Vor Bio's main focus in biotechnology?
Vor Bio is focused on transforming the treatment of autoimmune diseases through innovative therapies like telitacicept.
When is the oral presentation of the Phase 3 study results?
The oral presentation will take place on October 29, 2025, at 10:50am PT during the Annual Meeting in San Francisco.
What is telitacicept designed to treat?
Telitacicept is designed to treat autoimmune diseases by inhibiting key cytokines that support B cell survival, reducing autoreactive B cells.
Where is telitacicept currently approved for use?
Telitacicept is approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis.
How many people are affected by generalized myasthenia gravis?
Approximately 90,000 people in the U.S., 140,000 in Europe, and 29,000 in Japan are living with generalized myasthenia gravis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VOR Insider Trading Activity
$VOR insiders have traded $VOR stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $VOR stock by insiders over the last 6 months:
- INTERCHANGE LLC REPROGRAMMED has made 0 purchases and 13 sales selling 5,745,614 shares for an estimated $11,189,522.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VOR Hedge Fund Activity
We have seen 16 institutional investors add shares of $VOR stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,329,810 shares (-67.4%) from their portfolio in Q2 2025, for an estimated $7,014,292
- UBS GROUP AG added 1,523,181 shares (+18015.2%) to their portfolio in Q2 2025, for an estimated $2,467,553
- LYNX1 CAPITAL MANAGEMENT LP removed 637,218 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $457,203
- HRT FINANCIAL LP added 474,575 shares (+inf%) to their portfolio in Q2 2025, for an estimated $768,811
- SCIENTECH RESEARCH LLC added 403,859 shares (+inf%) to their portfolio in Q2 2025, for an estimated $654,251
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 384,293 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $622,554
- JANE STREET GROUP, LLC added 330,857 shares (+169.9%) to their portfolio in Q2 2025, for an estimated $535,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VOR Analyst Ratings
Wall Street analysts have issued reports on $VOR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/14/2025
To track analyst ratings and price targets for $VOR, check out Quiver Quantitative's $VOR forecast page.
$VOR Price Targets
Multiple analysts have issued price targets for $VOR recently. We have seen 4 analysts offer price targets for $VOR in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/14/2025
- Jack Allen from Baird set a target price of $1.0 on 06/27/2025
- David Nierengarten from Wedbush set a target price of $0.4 on 06/26/2025
- Silvan Tuerkcan from JMP Securities set a target price of $6.0 on 05/09/2025
Full Release
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California.
Oral Presentation Details
Abstract Title: Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study
Session: MGFA (Myasthenia Gravis Foundation of America)
Date & Time: October 29, 2025, at 10:50am PT
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit
www.vorbio.com
.
About Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan.
About Generalized Myasthenia Gravis
gMG is a rare, chronic autoimmune neuromuscular disorder that disrupts communication between nerves and muscles, leading to muscle weakness that can impact mobility, vision, swallowing, and breathing. The disease is mediated by autoantibodies, most commonly targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), which interfere with neuromuscular transmission. While several therapies are available, many patients continue to experience persistent symptoms or intolerable side effects. As a result, there remains a significant unmet need for new therapies that offer durable efficacy, a favorable safety profile, and convenient administration to improve the quality of life for people living with gMG. There are approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan living with the disease.
Media & Investor Contacts:
Carl Mauch
[email protected]
Sarah Spencer
[email protected]
